Wave Banks $170m Upfront In GSK Oligonucleotide Deal, Analysts Back Shift To Partnership Model
Lucrative Potential Milestones
The US biotech has out-licensed a preclinical candidate to GSK as the firms pair up to discover and develop multiple oligonucleotide assets.
